Trial Tackling Hepatitis C With New Drug
Conatus Pharmaceuticals Initiates Second Phase-II Hepatitis Trial
By Staff Reporter
CTS-1027 is an oral, small molecule compound that inhibits the activity of matrix metalloproteinases
Conatus Pharmaceuticals (Conatus) has initiated the second phase-II clinical trial with a drug candidate, for the treatment of liver disease associated with Hepatitis C Virus (HCV) infection. The trial will enroll patients for whom treatment with approved standard of care treatments is not currently advised.
CTS-1027 is an oral, small molecule compound that inhibits the activity of key members of a class of protease enzymes, the matrix metalloproteinases or MMPs. CTS-1027 had previously shown to be effective in multiple preclinical models of inflammatory liver disease and HCV infection.
The clinical trial is a double-blind, placebo-controlled trial, testing an optimized dose of CTS-1027 alone or in combination with ribavirin. Dosing will last for up to 24 weeks. The company expects approximately 70 patients to be enrolled. The clinical trial will be conducted at 25 medical centers in the US.
Results from an earlier clinical trial in HCV patients who failed standard of care treatment, are expected to be reported later this year.
URL for Article Source:
Apple CEO Gets Hotly Debated Liver Transplant
HCV Research and Development Company a Promising Investment